Citius Pharmaceuticals Reports LYMPHIR Revenue Growth, Explores CAR-T Combination
Citius Pharmaceuticals reported LYMPHIR (denileukin diftitox-cxdl) revenue of $7.1M for the first nine months of fiscal 2026 and 77% gross margin. Company data presented at ASTCT/CIBMTR showed 86% ORR and 57% CR in a Phase 1 CAR-T combination setting. ASCO investigator data in gynecologic malignancies showed 24% ORR. Cash was $17.0M at June 30, 2026.
How this was made
The 30-second read
Why it matters
The text links early clinical response rates in DLBCL (prior to CAR-T) and gynecologic malignancies to commercial traction indicators (vial orders, institutions, gross margin) while also stressing cash and burn dynamics that could force additional capital if uptake does not accelerate.
Market read
Traders get a near-term catalyst map: watch whether post-expansion institutional vial orders sustain after July’s record 383 vials, against a backdrop of ongoing operating losses and finite cash.
What to watch
The commercial team expansion completed only in August, so recognized revenue may lag capacity; traders should focus on whether order growth converts into sustained revenue without triggering additional dilution.
Background
LYMPHIR (denileukin diftitox-cxdl) was approved in August 2024 for relapsed or refractory cutaneous T-cell lymphoma, and this article adds early Phase 1 combination and investigator-initiated expansion signals.
Ticker impact
Citius reported LYMPHIR revenue of $7.1M for the first nine months of FY2026 and highlighted new Phase 1 readouts exploring CAR-T combinations.
Moderate upside bias on sustained vial-order momentum; downside risk if August-September orders fail to accelerate versus the post-expansion team ramp.
The article provides concrete commercial metrics (vials, institutions, gross margin) and early clinical response rates, but it also emphasizes ongoing operating losses and limited cash runway, making the next order-trend datapoints the swing factor.
Market effects
If LYMPHIR’s CAR-T sequencing shows durable responses, it could strengthen the competitive narrative for CTCL and broaden interest in combination immunotoxin strategies.
Primarily US biotech sentiment, driven by conference readouts and US commercial uptake metrics.
Limited direct global read-through, but combination-therapy interest can influence broader oncology investor appetite.
Counterpoint
Conference readouts are early and not yet tied to a company-sponsored pivotal program, so the market may overprice the combination signal before confirmatory data.
Key entities
- companyCitius Pharmaceuticals
Reports LYMPHIR revenue, gross margin, institutional vial-order growth, and early Phase 1 readouts exploring CAR-T combinations and other indications.
- productLYMPHIR (denileukin diftitox-cxdl)
Approved CTCL therapy; the article presents early response data in DLBCL prior to CAR-T and in recurrent or refractory gynecologic malignancies.
- service_providerEVERSANA
Commercial operations partner referenced for the expanded institutional coverage ramp.
